Determining the Efficacy and Value of Immunotherapy on the Likelihood of Peanut Tolerance: The DEVIL Study (DEVIL)
This study has been completed.
University of North Carolina, Chapel Hill
Information provided by (Responsible Party):
Wesley Burks, MD, University of North Carolina, Chapel Hill
First received: July 2, 2009
Last updated: April 17, 2017
Last verified: April 2017
No Study Results Posted on ClinicalTrials.gov for this Study
|Study Status:||This study has been completed.|
|Study Completion Date:||February 1, 2017|
|Primary Completion Date:||February 1, 2017 (Final data collection date for primary outcome measure)|
Vickery BP, Berglund JP, Burk CM, Fine JP, Kim EH, Kim JI, Keet CA, Kulis M, Orgel KG, Guo R, Steele PH, Virkud YV, Ye P, Wright BL, Wood RA, Burks AW. Early oral immunotherapy in peanut-allergic preschool children is safe and highly effective. J Allergy Clin Immunol. 2017 Jan;139(1):173-181.e8. doi: 10.1016/j.jaci.2016.05.027. Epub 2016 Aug 10.